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AIMS
In September 2012 the UK’s Commission on Human Medicines (CHM) recommended changes in
the management of paracetamol poisoning: use of a single ‘100 mg l−1’ nomogram treatment line,
ceasing risk assessment, treating all staggered/uncertain ingestions and increasing the duration of
the initial acetylcysteine (NAC) infusion from 15 to 60 min. We evaluated the effect of this on
presentation, admission, treatment, adverse reactions and costs of paracetamol poisoning.
METHODS
Data were prospectively collected from adult patients presenting to three large UK hospitals from
3 September 2011 to 3 September 2013 (year before and after change). Infusion duration effect on
vomiting and anaphylactoid reactions was examined in one centre. A cost analysis from an NHS
perspective was performed for 90 000 patients/annum with paracetamol overdose.
RESULTS
There were increases in the numbers presenting to hospital (before 1703, after 1854; increase 8.9%
[95% CI 1.9, 16.2], P = 0.011); admitted (1060/1703 [62.2%] vs. 1285/1854 [69.3%]; increase 7.1%
[4.0, 10.2], P < 0.001) and proportion treated (626/1703 [36.8%] vs. 926/1854 [50.0%]; increase:
13.2% [95% CI 10.0, 16.4], P < 0.001). Increasing initial NAC infusion did not change the proportion
of treated patients developing adverse reactions (15 min 87/323 [26.9%], 60 min 145/514 [28.2%];
increase: 1.3% [95% CI –4.9, 7.5], P = 0.682). Across the UK the estimated cost impact is £8.3 million
(6.4 million–10.2 million) annually, with a cost-per-life saved of £17.4 million (13.4 million–21.5
million).
CONCLUSIONS
The changes introduced by the CHM in September 2012 have increased the numbers of patients
admitted to hospital and treated with acetylcysteine without reducing adverse reactions. A safety
and cost-benefit review of the CHM guidance is warranted, including novel treatment protocols
and biomarkers in the assessment of poisoning.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Management of paracetamol poisoning is different in
the UK from other countries following a decision by the
Commission on Human Medicines (CHM) in 2012,
including treatment at the ‘100 mg l−1’ nomogram line,
stop risk assessment.
• The impact of this advice on patients is unclear.
• The CHM also advised change in the rate of initial
infusion in an attempt to reduce adverse drug reactions
(ADRs).
WHAT THIS STUDY ADDS
• The change has resulted in a highly significant increase
in admissions and the proportion of patients treated for
paracetamol poisoning (estimated UK effect: 31.1
thousand pre-change; 49.0 thousand post-change).
• The net effect is to treat many low risk patients and in
the NHS cost per life saved is £17.4 million.
• The change in initial acetylcysteine infusion does not
result in any reduction in ADR frequency.
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Introduction
Paracetamol poisoning is the most common acute over-
dose seen in industrialized countries [1, 2]. It is estimated
that between 82 000 and 90 000 patients present in the UK
each year with paracetamol overdose [3–5]. Between 150
and 250 deaths occur annually, the vast majority in
patients who have presented late, after a staggered over-
dose or after unintentional therapeutic excess [6–9].
Deaths or episodes of liver failure in patients [10] who
present and are treated within 8 h of a single acute inges-
tion are extremely rare [1, 5, 11].
The main reason for the relatively low number of
deaths is the availability of a highly effective antidote,
acetylcysteine (NAC) [12], which has been administered
intravenously using the same complex regimen since the
1970s. This has involved three weight-related doses of
NAC given intravenously in 5% dextrose over three differ-
ent time frames: 150 mg kg–1 body weight over 15 min,
followed by 50 mg kg–1over 4 h and 100 mg kg–1over 16 h.
In other parts of the world, notably North America and
Australia, the initial dose is given over 60 min rather than
15 min. In the UK, treatment has been recommended
for most patients with acute overdose who have a
timed plasma paracetamol concentration above the
‘200 mg l−1’ line on a nomogram (Figure 1) after a single
acute ingestion or a dose of 150 mg kg−1 or more within
24 h of a staggered ingestion or where the time of inges-
tion was unknown [13]. Patients with risk factors for
hepatotoxicity (poor nutrition, chronic alcohol excess,
enzyme inducing drugs) were given NAC if their timed
blood paracetamol concentration was above the ‘100’
line, or they had ingested more than 75 mg kg−1 within
24 h [21].
The NAC regimen is associated with a high incidence of
adverse effects, in particular vomiting and anaphylactoid
reactions [8–10, 14]. Because these occur during or soon
after infusion of the first 15 min bag [14, 15], this is given
over 60 min in some countries in the hope of reducing
adverse effects, although the one trial that assessed this
question did not find a difference [16]. Importantly,
anaphylactoid reactions are more frequent when NAC is
administered to patients with relatively low concentra-
tions of paracetamol [15, 17]. Anaphylactoid reactions are
unpleasant for patients, result in temporary cessation of
therapy, extend treatment and admission duration and
sometimes cause doctors to withhold effective treatment
from patients who need it [1, 18].
In September 2012, the UK’s Commission on Human
Medicines (CHM) reviewed the use of NAC in the man-
agement of paracetamol overdose. This followed the case
of a patient who had not been treated with NAC at first
presentation due to the timed paracetamol concentra-
tion being below recommended treatment thresholds,
who subsequently developed fatal hepatotoxicity. The
review identified nine further UK patients since 1991
who had also died after being initially assessed as not
requiring NAC. Three key recommendations arose from
the CHM review. First to use a single lower ‘100 mg l−1’
line on the nomogram for all patients with acute over-
dose and to stop assessing risk factors in deciding their
need for treatment, on the basis that use of risk factor
assessment was poor and inconsistent, and that many of
the risk factors were imprecise and difficult to determine
with sufficient certainty in clinical practice [5]. Second to
treat all patients with staggered overdose or unknown
time of ingestion with NAC. Third to change the duration
of the initial NAC infusion from 15 to 60 min, in an
attempt to reduce the risk of adverse reactions [5]. These
changes were subsequently endorsed by the UK Depart-
ments of Health, but not subjected to formal cost-benefit
analysis.
These changes in management guidance resulted in a
lower treatment threshold for paracetamol poisoning
in the UK than in most other countries, including the
USA, Canada, Australia and New Zealand, where a ‘150’
(Rumack-Matthew) line is used [19]. An exception is
Denmark, where all patients with a suspected overdose
receive antidote [5]. Although Ireland has subsequently
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also introduced the CHM changes, clinical toxicologists
in other countries have thus far rejected it [20]. Of
note, the change increases the number of patients with
low blood paracetamol concentrations receiving NAC,
potentially increasing the number of patients at risk of
developing anaphylactoid reactions. An initial report for
the first 6 months after the change in York showed sub-
stantial increases in admissions following the change in
guidance [4].
We therefore evaluated the effect of the change (i) on
the NHS by examining presentations, admissions, treat-
ment and estimated national cost of treating paracetamol
poisoned patients and (ii) on patients in terms of adverse
reactions to the antidote, especially in those with low
paracetamol concentrations. Costs were related to
numbers of lives expected to be saved, according to CHM
projections.
Methods
Data for audit of the management of paracetamol over-
dose are routinely and prospectively collected on data-
bases held within the clinical toxicology units of the Royal
Infirmary of Edinburgh, the Royal Victoria Infirmary, New-
castle upon Tyne and Guy’s and St Thomas’ NHS Founda-
tion Trust, London. The use of these databases for audit
has approval of the data protection officers/Caldicott
Guardians of NHS Lothian Health Board and of the New-
castle Hospitals and Guy’s and St Thomas’ NHS Foundation
Trusts.
Data on patients presenting to the Emergency
Departments and discharged, without admission to the
toxicology units, were also recorded. Data on treatment
indication and adverse events were collected by specialist
toxicology nurses, database scientists, senior medical
trainees and consultant clinical toxicologists. In addition,
in Edinburgh, use and timing of administration of treat-
ments for anaphylactoid reactions and vomiting following
commencement of NAC was routinely extracted from the
medication administration record (drug kardex) in combi-
nation with the medical notes.
The data collected included: patient demographics;
nature of the overdose (acute or staggered [i.e. repeated
excess therapeutic ingestion or repeat overdose, i.e. over
more than 60 min]), time from ingestion to presentation
for single acute ingestions (0–8 h, >8–24 h, >24 h, and
unknown time), plasma paracetamol concentration at
time of presentation, history of paracetamol dose, use of
NAC, nomogram treatment line [21] and need for addi-
tional NAC beyond the original 21 h infusion.
Patients
All patients presenting to the Emergency Departments of
the three hospitals with paracetamol overdose for 2 calen-
dar years, from 3 September 2011 until and including 3
September 2013 were eligible for inclusion in this study,
except those seen or admitted on 3 September 2012, who
were excluded as the CHM recommendations were pub-
lished and implemented that day. Eligible patients were
those reporting ingestion of (i) >4 g of paracetamol, alone
or in combinationwith other drugs, as a single ingestion or
over any 24 h period, (ii) <4 g where the blood results indi-
cated the need for NAC or (iii) an unknown amount of
paracetamol.
In Edinburgh, 150 patients requiring NAC were
recruited to the SNAP randomized clinical trial (RCT) of
anti-emetics and a novel regimen of NAC during the study
period (starting September 2010, terminating 31 Decem-
ber 2012) [18]. These patients were excluded from the
adverse reaction analysis since they were included in the
RCT. The CHM change in management was introduced on
3 September 2012. Prior to this date, all patients received
an initial NAC infusion over 15 min. All patients admitted
on or after this date, except for those recruited to the RCT,
were treated with an initial acetylcysteine infusion over
60 min.
Cost estimation
Building on the work of McQuade and colleagues [3],
we estimated costs from an NHS perspective using
NHS financial year 2011–12 reference costs (HRG4) for
three different diagnostic groups (https://www.gov.uk/
government/publications/nhs-reference-costs-financial-
year-2011-to-2012). For those discharged home from the
emergency department, we used VB08Z [Emergency
Medicine, Category 2 Investigation with Category 1 Treat-
ment (Toxicology investigation other treatment)] to give
£137 per case. For admitted patients not treated we used
VB08Z [Emergency Medicine, Category 2 Investigation
with Category 1 Treatment (Toxicology investigation
other treatment)] cost (£137) and PA50Z [Ingestion poi-
soning] in-patient episode cost (£572), giving a total of
£709. For those admitted and treated with NAC, we used
VB04Z [Emergency Medicine, Category 2 Investigation
with Category 4 Treatment (Toxicology investigation with
i.v. drug treatment)] cost (£196) and PA50Z [Ingestion
poisoning] in-patient episode cost (£572), giving an
overall cost of £768 per case. We applied these costs
equally across the 2 calendar year periods before and
after the change to ensure comparability between time
frames.
The number of patients admitted to hospital in the UK
can be taken from hospital activity statistics, but there are
no good sources tomeasure accurately all hospital attend-
ances with paracetamol overdose, as many are discharged
and admission rates vary. The MHRA estimated that there
are 68–70 000 presentations in England and Wales, and
including Scottish data, an estimated 82–90 000 patients
are seen per annum with deliberate or accidental
paracetamol overdose [5].
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Statistical analysis
Demographic details of patients included in the analysis
were illustrated by simple descriptive statistics. Continu-
ous variables were presented as medians and ranges. Cat-
egorical variables were compared using chi-squared tests.
Differences between proportions were compared by
testing for their equality.
In order to assess as objectively as possible the rates of
adverse reactions, the analysis concentrated on the use of
medication to treat adverse events normally associated
with acetylcysteine use, vomiting or anaphylactoid
reactions. Medications were either anti-emetics such
as ondansetron or cyclizine, antihistamines (generally
chlorphenamine) or bronchodilators such as salbutamol.
Rates of treatments for adverse reactions were calcu-
lated overall for all patients, and then by the 15 or 60 min
treatment groups. Patients were then grouped by both
treatment regimens and initial paracetamol concentration
(below or above 100 mg l−1) and the rates of medication
use in these groups compared.
Results are expressed as totals or proportions (%) of
patients who had therapy for adverse effects following
therapy. Statistical analysis was conducted usingWilcoxon
rank-sum test and measurement of odds ratios (OR) and
95% CIs. Multivariable logistic regression was used to
investigate the odds of reaction by infusion type and
paracetamol concentration.
Results
Presentation, admissions, and NAC treatment
For the calendar year before and after the change, 3 Sep-
tember 2011 to 3 September 2013, and ignoring the day of
the change, 3557 patients with paracetamol poisoning
presented to the three participating hospitals (Table 1). A
total of 1703 presented in the year before (03/09/11–02/
09/12), and 1854 in the year after (04/09/12–03/09/13), a
relative increase of 8.9% (95% CI 1.9, 16.2, P = 0.011)
(Table 1). This increase remained consistent throughout
the following year (Figure 2).
Comparing the year after the change with the year
before, a greater proportion of patients were admitted
to hospital (before 1060/1703 [62.2%], after 1285/1854
[69.3%]; absolute increase 7.1%, 95% CI 4.0, 10.2, P < 0.001)
and more patients were treated with NAC (before 626/
1703 [36.8%], after 926/1854 [50.0%]; absolute increase
13.2%, 95% CI 10.0, 16.4, P < 0.001) (Table 2, Figure 2).
Table 1
Presentations, admissions and use of NAC across three UK hospitals
Pre Post
Change
+/− 95% CI P
Presentations (n)
Centre 1 990 1111 12.2% 3.0, 22.3 0.008
Centre 2 378 386 2.1% −11.4, 17.6 0.772
Centre 3 335 357 6.6% −8.2, 23.7 0.403
Overall 1703 1854 8.9% 1.9, 16.2 0.01
Admitted (%)
Centre 1 54.7 (541/990) 63.1 (701/1111) 8.5% 4.2, 12.7 <0.001
Centre 2 79.1 (299/378) 86.8 (335/386) 7.7% 2.4, 13.0 0.005
Centre 3 65.7 (220/335) 69.8 (249/357) 4.1% −2.9, 11.0 0.251
Overall 62.2 (1060/1703) 69.3 (1285/1854) 7.1% 4.0, 10.2 <0.001
Treated with NAC (%)
Centre 1 39.0 (386/990) 49.6 (551/1111) 10.6% 6.4, 14.8 <0.001
Centre 2 30.4 (115/378) 50.3 (194/386) 19.8% 13, 26.7 <0.001
Centre 3 37.3 (125/335) 50.7 (181/357) 13.4% 6.2, 20.7 <0.001
Overall 36.8 (626/1703) 50 (926/1854) 13.2% 10.0, 16.4 <0.001
Centre 1 = Royal Infirmary of Edinburgh; centre 2 = Guy’s and St Thomas’ NHS Foundation Trust, London; centre 3 = Royal Victoria Infirmary, Newcastle upon Tyne.
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Figure 2
Patients admitted ( ) and treated ( ) for paracetamol poisoning
with acetylcysteine in the index hospitals during 2011–2013. Vertical
arrow indicates new MHRA guidance
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There was some evidence to suggest differences in
the patterns of poisoning before and after the change
(Chi-squared = 15.3, P = 0.003), with fewer presentations
0–8 h after overdose and more staggered presentations.
There were also more accidental presentations after the
change (Chi-squared = 14.0, P < 0.001) (Table 2). None of
the patients in this study was referred for liver unit care.
There were 1340 (78.7%) acute ingestions before the
change and 1357 (73.2%) afterwards, of these 822 were
admitted before and 917 afterwards, representing 61.3%
and 61.7% of these presentations, respectively, (absolute
increase 6.2% (95% CI 2.6, 9.8, P < 0.001). A lower propor-
tion of single ingestions were treated with NAC before the
change (32.4%, 435/1340) than afterwards (43.7%, 593/
1357) absolute increase 11.2% (95% CI 7.6, 14.9, P < 0.001).
For staggered overdoses (including therapeutic excess)
there were 309 before the change and 435 afterwards,
representing 18.1% and 23.5% of presentations, respec-
tively. Comparing before and after the change, there was
no statistical evidence of a difference in the proportion of
such cases admitted (215/309 [69.6%] vs. 327/435 [75.2%];
absolute increase 5.6%, 95% CI 0.1, 12.1, P = 0.091).
However, the proportion treated with NAC increased (178/
309 [57.6%] vs. 300/435 [69.5%]; absolute increase 11.4%,
95% CI 4.3, 18.4, P = 0.001).
There was no reduction after the change in the number
of patients who required extended treatment with NAC on
review of the blood results taken around the end of bag
three. Based on data from Edinburgh, 43 patients (4.3%,
43/990) required additional NAC before the change com-
pared with 43 (3.9%, 43/1111) after the change (absolute
change −0.5%, 95% CI −2.2, 1.2, P = 0.587).
Incidence and timing of adverse drug reactions
to acetylcysteine
The number of recorded ADRs increased substantially fol-
lowing the change in guidance. However, the proportion
of treated patients experiencing ADRs was unchanged
(before 87/323 [26.9%], after 145/514 [28.2%]; absolute
increase 1.3%, 95% CI −4.9, 7.5, P = 0.682). This was also the
case for anaphylactoid reactions (before 29/323 [9.0%],
after 55/514 [10.7%]; absolute increase 1.7%, 95% CI −2.4,
5.8, P = 0.426) (Table 3). The time of onset of these reac-
tions following initiation of NAC was later after the change
(83.2 min, IQR 50 to 95) compared with before (47.5 min,
IQR 20 to 50, Wilcoxon rank-sum, P < 0.001, Tables 4 and 5).
Association of adverse reactions with
infusion duration
To determine whether changing the duration of infusion
had affected the incidence of adverse reactions, we per-
formed a multivariable analysis, while controlling for the
paracetamol concentration, gender and age. The analysis
included a total of 837 patients, 323 (215 acute, 105 stag-
gered, three unknown) treated using an initial 15 min
infusion of NAC and 514 (325 acute, 177 staggered, 12
unknown) treated using a 60 min initial infusion. The
median age and gender ratios did not differ between
patients treated at the different infusion rates (Table 4).
Rates of use of anti-emetic therapies did not differ
between patients receiving 15 min or 60 min infusions of
NAC (Table 3). After controlling for age, gender and pre-
senting paracetamol concentration, the odds of being
treated with anti-emetics did not differ in patients receiv-
ing a 60 min infusion compared with those treated with a
Table 2
Demographics of patients with paracetamol poisoning
Pre-change Post-change Total
n = 1703 n = 1844 n = 3547
Age (years) median (range) 32 (1–95) 31 (1–98) 2 (1–98)
Blood paracetamol (mg l−1)
median (range)*
37 (0–587) 30 (0–660) 32 (0–660)
Admitted n (%) 1060 (62.2) 1285 (69.3) 2345 (65.9)
Median age (years) (% F) 34 (57.4) 33 (60.2) 34 (58.9)
Discharged n (%) 643 (37.8) 569 (30.7) 1212 (34.1)
Median age (years) (% F) 30 (59.4) 29 (58.0) 30 (58.7)
Presentation times
0–8 h n (%) 1071 (62.9) 1077 (58.1) 2148 (60.4)
Median age (years) (% F) 32 (59.7) 30 (61.5) 31 (60.6)
>8–24 h n (%) 177 (10.4) 188 (10.1) 365 (10.3)
Median age (years) (% F) 28 (62.1) 30 (62.2) 29 (62.2)
>24 h n (%) 92 (5.4) 92 (5.0) 184 (5.2)
Median age (years) (% F) 32 (57.6) 35 (56.5) 34 (57.1)
Staggered n (%) 309 (18.1) 435 (23.5) 744 (20.9)
Median age (years) (% F) 36 (50.8) 34 (54.7) 36 (53.1)
Unknown n (%) 54 (3.2) 62 (3.3) 116 (3.3)
Median age (years) (% F) 37 (57.4) 42 (54.8) 40 (56.0)
Deliberate self-harm n (%) 1483 (88.2) 1535 (83.8) 3018 (85.9)
Median age (years) (% F) 32 (59.7) 31 (61.9) 31 (60.8)
Accidental n (%) 198 (11.8) 296 (16.2) 494 (14.1)
Median age (years) (% F) 34 (47.5) 38 (47.4) 36 (47.6)
Figures in brackets are 95% CIs or % in the patient group. *For statistical analysis
paracetamol concentrations below the level of detection for the laboratory have
been treated as zero.
Table 3
Patient demographics and reactions to treatment by infusion rate
15 min infusion
rate (n = 323)
60 min infusion
rate (n = 514)
Age (years) median (range) 36 (13–90) 33 (13–98)
Female 184 (57.0) 325 (63.2)
Blood paracetamol (mg l−1)
Median (range) 80 (0–424) 76.5 (3–660)
Adverse reactions n (%)
1. Vomiting only 58 (18.0) 90 (17.5)
2. Anaphylactoid only 13 (4.0) 38 (7.4)
3. Both vomiting and
anaphylactoid
16 (5.0) 17 (3.3)
4. All vomiting (1 + 3) 74 (22.9) 107 (20.8)
5. All anaphylactoid (2 + 3) 29 (9.0) 55 (10.7)
6. No reaction 236 (73.1) 369 (71.8)
Figures in brackets are 95% CIs or % in the patient group.
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15 min infusion (OR 0.85, 95% CI 0.61, 1.20, P = 0.367). In
the 495 patients presenting with blood paracetamol con-
centrations below 100 mg l−1, the longer infusion duration
was not associated with less use of anti-emetic therapy
(15 min 46/185 [24.9%] vs. 60 min 56/310 [17.1%}; OR 0.67,
95% CI 0.43, 1.05, P = 0.084).
The odds of an anaphylactoid reaction did not differ
according to the infusion duration, when controlled for
age, gender and presenting paracetamol concentration:
60 min 55/514 (10.7%) vs. 15 min 29/321 (9.0%, OR 1.22,
95% CI 0.75, 1.98, P = 0.414).
As seen in previous studies, we did find an excess
of anaphylactoid reactions in patients with lower para-
cetamol concentrations. Patients with presenting blood
paracetamol concentrations >100 mg l−1 (11/340) were
80% less likely to experience an anaphylactoid reaction
than those with blood paracetamol <100 mg l−1 (73/495;
OR 0.19, 95% CI 0.10, 0.37, P < 0.001). This association was
replicated in both the 15 min (OR 0.14, 95% CI 0.04, 0.48, P
< 0.001) and 60 min (OR 0.21, 95% CI 0.10, 0.47, P < 0.001)
treatment groups (Table 4).
Cost effects of the change
Before the change, an estimated 90 000 patients pre-
sented to hospitals across the UK and 45 000 were admit-
ted to hospital [5]. We observed an 8.9% (95% CI 1.9,
16.2) increase in presentations over the study period, a
7.1% (95% CI 4.0, 10.2) increase in the proportion of
patients admitted, and a 13.2% (95% CI 10.0, 16.4)
increase in use of antidote in admitted patients. We esti-
mated the cost implications of each aspect of patient
care, including patients not treated with NAC and dis-
charged from the emergency department or admitted,
and those admitted for NAC. We calculate that the full
annual cost of managing paracetamol overdose was
£40.0 million before the change and £48.3 million after-
wards, an absolute annual increase of £8.3 million (95% CI
6.4, 10.2 million) (Table 6).
The CHM estimated that the reduction in treatment
thresholds would save a life every 2.1 years [5]. On the
basis of this estimate and the data collected in the
current study, the cost-per-life saved for this change was
Table 4
Odds ratios of adverse events to treatment by infusion rate and presenting blood paracetamol
All vomiting All anaphylactoid
Events / n OR 95% CI P Events / n OR 95% CI P
Infusion rate1
All patients (n = 8353) 15 min 73/321 1 – – 29/321 1 – –
1 h 107/514 0.85 0.61, 1.20 0.368 55/514 1.22 0.75, 1.98 0.414
<100 mg l−1 patients (n = 495) 15 min 46/185 1 – – 26/185 1 – –
1 h 56/310 0.67 0.43, 1.05 0.084 47/310 1.10 0.66, 1.86 0.707
>100 mg l−1 patients (n = 340) 15 min 27/136 1 – – 3/136 1 – –
1 h 51/204 1.19 0.69, 2.04 0.527 8/204 2.15 0.54, 8.55 0.256
Paracetamol concentration2
All patients (n = 8353) >100 78/340 1.09 0.78, 1.53 0.618 11/340 0.19 0.10, 0.37 <0.001
<=100 102/495 1 – – 73/495 1 – –
15 min infusion (n = 321) >100 27/136 0.77 0.45, 1.33 0.354 3/136 0.14 0.04, 0.48 <0.001
<=100 46/185 1 – – 26/185 1 – –
1 h infusion (n = 514) >100 51/204 1.37 0.88, 2.12 0.163 8/204 0.21 0.10, 0.47 <0.001
<=100 56/310 1 – – 47/310 1 – –
Age4
All patients (n = 8353) <35 111/412 1 – – 45/423 1 – –
>=35 69/413 0.58 0.42, 0.82 0.002 39/414 0.82 0.51, 1.30 0.391
Gender5
All patients (n = 8353) Female 125/507 1 – – 51/507 1 – –
Male 55/328 0.66 0.46, 0.95 0.025 33/328 0.91 0.60, 1.51 0.688
1. Controlling for age, gender and presenting paracetamol concentration. 2. Controlling for age, gender and infusion rate. 3. one patient who had no data on blood paracetamol
concentration was excluded. 4. Controlling for gender, infusion rate and presenting paracetamol concentration. 5. Controlling for gender, infusion rate and presenting blood
paracetamol concentration.
Table 5
Total number of adverse reactions by time of reaction
Time from start infusion
Pre-change
group n (%)
Post-change
group n (%)
n = 87 n = 145
0–29 min 29 (33.3) 11 (7.6)
30–59 min 32 (36.8) 34 (23.5)
1–1 h 29 min 9 (10.3) 45 (31)
1 h 30 min–2 h 4 (4.6) 27 (18.6)
>2 h 5 (5.8) 19 (13.1)
Unknown time 8 (9.2) 9 (6.2)
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estimated to be £17.4 million (95% CI 13.4, 21.5 million)
(Table 6).
Discussion
This study provides evidence that the 2012 CHM guidance
for the management of paracetamol poisoning has
resulted in substantial increases in hospital presentations,
hospital admissions and NAC treatment courses, but an
apparent improved consistency in the proportion of
patients treated (with almost identical rates of 50% treat-
ment in the three participating hospitals compared with a
previous range of 31 to 39%). In spite of the slower initial
infusion rate, there has been no decrease in the proportion
of people developing themore severe adverse reactions to
acetylcysteine that require treatment.
The increase in presentation rate is, at least in part, in
patients with chronic therapeutic or staggered parace-
tamol overdose. The CHM guidance has resulted in a sig-
nificant increase in calls from NHS public telephone advice
services (NHS Direct, NHS111 and NHS24) for advice on
suspected paracetamol overdose and hospital referrals
[22]. Although the CHM guidance defined staggered over-
dose in terms of duration of consumption, the amount of
paracetamol required to constitute an overdose needing
acetylcysteine was not defined and this may have
increased hospital referrals and treatment for patientswith
modest overdoses.
Modelling of the national impact of the CHM advice
relies on the assumption that changes seen in these three
hospitals are representative of changes that have occurred
across the UK. This seems a reasonable approach, particu-
larly as there was consistency in the proportion of patients
treated with acetylcysteine across the three centres. A
shorter study elsewhere also found an increase in admis-
sions following the change in advice [4]. The increases in
hospital activity as a result of the change in guidance are
expensive, costing theNHS an estimated £8.3million every
year, with a cost per life saved of £17.4 million.
The study found that the rates of vomiting requiring
anti-emetic therapy and of anaphylactoid reactions were
little different with a 60 min infusion as compared with a
15 min infusion, even in patients with low paracetamol
concentrations, although they were delayed in patients
receiving the 60 min infusion (Table 5). It also confirmed a
much higher rate of anaphylactoid reactions in those with
lower paracetamol concentrations. The changes to the
initial acetylcysteine infusion rate recommended by the
CHM have therefore not reduced the rates of adverse reac-
tions. However, the patients affected by the change who
have lower paracetamol concentrations and a low risk of
hepatic injury and who are now being treated with NAC,
have the highest risk of anaphylactoid reactions.
Newer approaches that might reduce rates of
anaphylactoid reactions are clinically needed, and thisTa
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might include the use of different acetylcysteine infusion
schedules such as we have recently described [18].
Limitations
The data come from three specialist centres, in London,
Northern England and Scotland, and may not precisely
reflect the whole of the UK. The London centre treated
proportionally fewer patients in the pre-change year, and
if this is representative of southern England as a whole the
cost impact of change is even greater than we show.
However, the centres see many paracetamol poisoned
patients. Indeed, data from Edinburgh were used by the
CHM in its risk assessment. We therefore consider that
the changes we have found are likely to reflect national
activity. While statistics in England as reflected in hospital
activity analysis (available from http://www.hscic.gov.uk/
hes) to March 2013 do not show an immediate change,
there are several factors that may explain this, particularly
coding methodologies, and time delays in actual coding.
Coding has previously been shown weak in other types of
poisoning [23], and importantly these data sets also do not
provide information on proportions treated. In contrast,
an 18% increase in annual hospital admissions with
paracetamol poisoning (ICD10 T39.1) has been seen in
Scotland, comparing the years before and after October
2012, which is similar to the increase reported in this paper
(source NSD Scotland 2014).
We have not accounted for any reduced costs as a
result of fewer cases of severe hepatic injury in patients
who would have been untreated using the previous man-
agement guidelines. However we foresee few savings, as,
although costs of hepatic intensive care are very high,
serious hepatic injury and death are very rare in this
patient group, and mortality in patients not treated with
NAC is estimated at one death every 2.1–2.2 years [5]. The
small increase in the rate of anaphylactoid reactions would
have resulted in more treatment interruptions and there-
fore longer stays in hospital. Since neither of these is
reflected in the Healthcare Resource Group costs, they are
not included in this cost analysis.
It should be noted that some deaths previously occur-
ring in patients presenting between the ‘100’ and ‘200’
lines may not be known to theMHRA. If this is the case, the
numbers of lives that might be saved by the change in
guidance would be underestimated and the costs per life
saved overestimated. However, treatment at these lower
paracetamol concentration thresholds is unlikely to reach
conventional thresholds for cost effectiveness unless the
actual numbers of deaths had been underestimated many
fold. It is also likely that not all fatal adverse reactions to
acetylcysteine have been reported to the MHRA and this
would have the opposite effect. As theMHRA is only aware
of one death occurring in a patient presenting with a
paracetamol concentration between the ‘100’ and ‘150’
lines, treatment of this less severely poisoned subgroup
would carry a much higher cost-per-life saved. We
acknowledge, however, that considerations of cost-
effectiveness of treatments are outside the remit of the
CHM and the MHRA.
In the adverse reactions analysis, we only analyzed
cases from one unit (the busiest) that received rescue
treatments such as anti-emetics or antihistamines. This will
underestimate true adverse reaction rates, as less severe
symptoms may not be reported or treated. Of note,
adverse reaction rates in the control arm of our prospec-
tive clinical trial were significantly greater, with 78% of
patients suffering nausea or vomiting, and 30% suffering
an anaphylactoid reaction severe enough to require inter-
ruption of acetylcysteine infusion or rescue therapy [18].
In conclusion, we have shown that the CHM changes
have resulted in significant increases in rates of hospital
presentation and admission, in use of acetylcysteine and in
adverse reactions, at substantial cost. None of this cohort
of over 3500 patients required liver unit referral before or
after the CHM change, emphasizing the rarity of serious
liver injury with either management strategy. As we, and
others, have previously reported, most episodes of hepa-
totoxicity occur as a result of late presentation to hospital,
and this should be a target for public health intervention
[6, 11]. We believe a full safety/efficacy review of the new
CHM recommendations is now needed, together with a
detailed cost-effectiveness analysis. In view of the sub-
stantial increases in hospital presentations and use of
acetylcysteine in patients with staggered overdose or
therapeutic excess, this should include better definitions
of the amount of paracetamol required to constitute an
overdose needing acetylcysteine, potential for use of
novel biomarkers [24] and alternative regimens for deliv-
ering acetylcysteine that have lower rates of adverse
effects [18].
Competing Interests
All authors have completed the Unified Competing Inter-
est form at http://www.icmje.org/coi_disclosure.pdf (avail-
able on request from the corresponding author) and
declare no support from any organization for the submit-
ted work and no financial relationships with any organiza-
tions that might have an interest in the submitted work in
the previous 3 years; DJW has been a member of the
Agency Board at MHRA since 1 September 2013. SHLT is a
member of the UK Commission on Human Medicines and
was amember of the CHMParacetamol Expert Group. DNB
presented evidence to the CHM Paracetamol Expert
Group. SHLT, JD and ME were members of the MHRA ad
hoc sub-groups to advise on the implementation of
changes to themanagement of paracetamol overdose and
on necessary research. RC is funded by a National Institute
of Health Research (NIHR) Doctoral Research Fellowship.
ME is a Scottish Senior Clinical Fellow, funded by CSO and
Impact of UK acetylcysteine guidance changes
Br J Clin Pharmacol / 78:3 / 617
Scottish Funding Council, and a Lister Research Prize
Fellow. All other authors declare that they have no con-
flicts of interest.
We thank all staff at the participating centres who
assisted in the care of the patients reported in this study. We
are grateful for advice from Andrew Stoddart, Edinburgh’s
Health Services Research Unit on NHS costs.
REFERENCES
1 Ferner RE, Dear JW, Bateman DN. Management of
paracetamol poisoning. BMJ 2011; 342: d2218.
2 Heard KJ. Acetylcysteine for acetaminophen poisoning.
N Engl J Med 2008; 359: 285–92.
3 McQuade DJ, Dargan PI, Keep J, Wood MD. Paracetamol
toxicity: what would be the implications of a change in UK
treatment guidelines? Eur J Clin Pharmacol 2012; 65:
1541–7.
4 Thompson G, Fatima SB, Shah N, Kitching G, Waring WS.
Impact of amending the acetylcysteine marketing
authorisation on treatment of paracetamol overdose. ISRN
Toxicol 2013; 2013: doi:10.1155/2013/494357.
5 MHRA. Benefit risk profile of acetylcysteine in the
management of paracetamol overdose. [Internet]. 2012.
Available at: http://www.mhra.gov.uk/home/groups/
pl-p/documents/drugsafetymessage/con184709.pdf (last
accessed 13 May 2013).
6 Pakravan N, Simpson KJ, Waring WS, Bates CM, Bateman DN.
Renal injury at first presentation as a predictor for poor
outcome in severe paracetamol poisoning referred to a liver
transplant unit. Eur J Clin Pharmacol 2009; 65: 163–8.
7 Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC,
Simpson KJ. Staggered overdose pattern and delay to
hospital presentation are associated with adverse outcomes
following paracetamol-induced hepatotoxicity. Br J Clin
Pharmacol 2012; 73: 285–94.
8 Whyte IM, Francis B, Dawson AH. Safety and efficacy of
intravenous N-acetylcysteine for acetaminophen overdose:
analysis of the Hunter Area Toxicology Service (HATS)
database. Curr Med Res Opin 2007; 23: 2359–68.
9 Lynch RM, Robertson R. Anaphylactoid reactions to
intravenous N-acetylcysteine: a prospective case controlled
study. Accid Emerg Nurs 2004; 12: 10–5.
10 Waring WS, Pettie JM, Dow MA, Bateman DN. Paracetamol
appears to protect against N-acetylcysteine-induced
anaphylactoid reactions. Clin Toxicol 2006; 44: 441–2.
11 Beer C, Pakravan N, Hudson M, Smith LT, Simpson K,
Bateman DN, Thomas SH. Liver unit admission following
paracetamol overdose with concentrations below current
UK treatment thresholds. QJM 2007; 100: 93–6.
12 Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam
RD, Proudfoot AT. Treatment of paracetamol
(acetaminophen) poisoning with N-acetylcysteine. Lancet
1977; 2: 432–4.
13 Routledge PA, Vale JA, Bateman DN, Johnston GD, Jones A,
Judd A, Thomas S, Volans G, Prescott LF, Proudfoot A.
Paracetamol (acetaminophen) poisoning. No need to
change current guidelines to accident departments. BMJ
1998; 317: 1609–10.
14 Pakravan N, Waring WS, Bateman DN. Risk factors and
mechanisms of anaphylactoid reactions to acetylcysteine in
acetaminophen overdose. Clin Toxicol 2008; 46: 697–702.
15 Schmidt L. Identification of patients at risk of anaphylactoid
reactions to N-acetylcysteine in the treatment of
paracetamol overdos. Clin Toxicol 2013; 51: 467–72.
16 Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins
A, Chan B, Trudinger B. The Australasian Clinical Toxicology
Investigators Collaboration randomized trial of different
loading infusion rates of N-acetylcysteine. Ann Emerg Med
2005; 45: 402–8.
17 Waring WS, Stephen AF, Robinson OD, Dow MA, Pettie JM.
Lower incidence of anaphylactoid reactions to
N-acetylcysteine in patients with higher acetamonophen
concentrations after overdose. Clin Toxicol 2008; 46:
496–500.
18 Bateman DN, Dear JW, Thanacoody HKR, Thomas SHLT,
Eddleston M, Sandilands EA, Coyle J, Cooper JG, Rodriguez
A, Butcher I, Lewis SC, Vliegenthart AD, Veiraiah A, Webb DJ,
Gray A. Reducing adverse effects from intravenous
acetylcysteine treatment of paracetamol poisoning: a
randomised controlled trial. Lancet 2014; 383: 697–704.
Published online November 28, 2013. http://dx.doi.org/
10.1016/S0140-6736(13)62062-0.
19 Rumack BH, Matthew H. Actaminophen poiosning and
toxicity. Paediatrics 1975; 55: 871–6.
20 Gosselin S, Hoffman RS, Juurlink DN, Whyte IM, Yarema M,
Caro J. Treating acetaminophen overdose: thresholds, costs
and uncertainties. Clin Toxicol 2013; 51: 130–3.
21 BNF. British National Formulary, 64th edn. London: BMJ
Group and RPS Publishing, 2012.
22 Adams RD, Crawford C, Perry L,Thomas SHL, Thompson JP,
Vale JA, Eddleston M. Paracetamol excess related to dental
pain in adults – NPIS enquiries pre and post MHRA guideline
changes. Clin Toxicol 2014; 52: 391–2.
23 Wood DM, Conran CP, Dargan PI. ICD-10 coding: poor
identification of recreational drug presentations to a large
emergency department. Emerg Med J. 2011; 28: 387–9.
24 Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M,
Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN,
Goldring CE, Park BK. Mechanistic biomarkers provide early
and sensitive detection of acetaminophen-induced acute
liver injury at first presentation to hospital. Hepatology
2013; 58: 777–87.
D. N. Bateman et al.
618 / 78:3 / Br J Clin Pharmacol
